StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Stock analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 2.4 %

CHEK opened at $1.29 on Monday. Check-Cap has a 52-week low of $1.13 and a 52-week high of $4.24. The company has a 50 day moving average of $1.83 and a two-hundred day moving average of $2.08. The company has a market cap of $7.55 million, a P/E ratio of -0.41 and a beta of 0.39.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.